Is TRXC stock a good buy?
TransEnterix currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
What is TRXC stock price?
Key Turning Points
| 52-Week High | 6.95 |
|---|---|
| Last Price | 4.08 |
| Fibonacci 50% | 3.62 |
| Fibonacci 38.2% | 2.83 |
| 52-Week Low | 0.28 |
Who is TRXC?
About TransEnterix (NYSEAMERICAN:TRXC) TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery.
What happened to Transenterix Inc?
“As the company evolves from a robotics company to a digital surgery company, the rebrand better reflects our vision and we know that Asensus has the technology, the team, and the opportunity to create a new paradigm in best surgical practices and techniques we call performance-guided surgery.”
Why TRXC change name?
The name change was aimed at better reflecting the company’s focus on cutting-edge technologies like computer vision and machine learning for robotic surgeries (“sensus” is Latin for “cognition” and the “A” is for “augmented intelligence).
Who owns Asensus Surgical?
The Vanguard Group, Inc.
Who owns Asensus surgical?
Is Asensus surgical?
Asensus Surgical is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™ by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery.
Where is Asensus surgical located?
Durham, North Carolina
Asensus Surgical is located in Durham, North Carolina, United States .
Will Asensus Surgical stock go up?
Stock Price Forecast The 1 analysts offering 12-month price forecasts for Asensus Surgical Inc have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 4.00. The median estimate represents a +931.46% increase from the last price of 0.39.
Is laparoscopy safer than open surgery?
Conclusions: Laparoscopic surgery has demonstrably better quality-of-life outcomes than open surgery for cholecystectomy, splenectomy, and esophageal surgery. However, open hernioplasty has at least as good, if not better, health status outcomes than laparoscopic repair.
What happened to ascensus surgical?
Asensus Surgical sells a robot-assisted surgery system called Senhance Surgical. After the market closed on Wednesday, the company reported third-quarter results that impressed investors. Unfortunately, demand for the Senhance Surgical system is too weak to produce a positive gross profit.
Will Bionano Genomics stock go up?
Stock Price Forecast The 3 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 8.00, with a high estimate of 12.00 and a low estimate of 6.00. The median estimate represents a +390.80% increase from the last price of 1.63.
What does ascensus surgical do?
The Senhance Surgical System is turbocharging the Digital Laparoscopy landscape, providing surgeons with an unprecedented level of control, integrating innovative technological advances to help surgery become more instinctive, more responsive and more focused.